Sanofi expanded the sales reach of the drug with approvals in the lucrative chronic obstructive pulmonary disease (COPD) market. Dupixent’s success pushed Sanofi’s total net sales to €9.9bn, up 10% at ...

Shares in French pharma major Sanofi were 6% lower late Thursday after the presentation of the company’s second quarter ...

The remainder of 2025 will be busy for Vir Biotechnology as it strives to successfully pivot to developing cancer and infectious disease therapies.

Following the positive opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on ...

As pharmaceutical import tariffs take shape in Europe, President Donald Trump is rounding out the week by spotlighting ...

ESTEVE acquires Regis Technologies, a United States-based Contract Development and Manufacturing Organization (CDMO), ...

Reported EPS is $0.2429 EPS, expectations were $0.63. Operator: Hello, and welcome to the Teva Pharmaceutical Industries ...

The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 ...

That's the top-line finding of the latest financing report from the UK BioIndustry Association (BIA), which reveals that ...

Muted enthusiasm for this week’s US-EU trade agreement did little to dispel concerns that the US has unfinished business with Ireland’s pharmaceutical sector.

An update from BB Biotech ( ($CH:BION) ) is now available. In Q2 2025, BB Biotech outperformed the Nasdaq Biotech Index, with a 10.2% increase in ...

Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma  Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction ...